Eli Lilly's Trajenta Fails Cost Benefit Assessment

BMI View: Despite the threat of austerity measures and the government's focus on cost-containment within the pharmaceuticals and healthcare sector, as well as the impact of generic competition as a result of the patent cliff, we expect Germany to remain attractive to innovative drugmakers. In 2011, Germany's drug market was the fourth largest globally after the US, Japan and China. Furthermore, per-capita spending is high, there is a sizeable pensionable population and regulations are transparent - factors BMI believes will continue to bring in substantial income for companies operating in the country.

To read the full article, please choose one of the following options: